<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>192 Ugandan patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were treated with various regimens containing high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>21 patients died during induction therapy, and 14 died after partial responses </plain></SENT>
<SENT sid="2" pm="."><plain>Of 157 patients who responded completely to treatment, 16 were lost to follow-up (10 in 69 died and 72 (51%) are alive and disease-free </plain></SENT>
<SENT sid="3" pm="."><plain>31 of the long-term survivors have relapsed at least once and have been successfully retreated </plain></SENT>
<SENT sid="4" pm="."><plain>Overall, 34 surviving patients had central-<z:mp ids='MP_0008912'>nervous</z:mp>-system involvement, also successfully treated </plain></SENT>
<SENT sid="5" pm="."><plain>It is concluded that Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is curable in at least 50% of patients, and that relapse and central-<z:mp ids='MP_0008912'>nervous</z:mp>-system involvement are not incompatible with long survival </plain></SENT>
</text></document>